China Resources Boya Bio pharmaceutical Group Co Ltd (300294) - Cash Flow Conversion Efficiency
Based on the latest financial reports, China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a cash flow conversion efficiency ratio of 0.005x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥36.82 Million ≈ $5.39 Million USD) by net assets (CN¥7.46 Billion ≈ $1.09 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of China Resources Boya Bio pharmaceutical for the company's overall valuation and market capitalisation.
China Resources Boya Bio pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
China Resources Boya Bio pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China Resources Boya Bio pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency. Explore 300294 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
0.038x |
|
AcadeMedia AB (publ)
ST:ACAD
|
0.200x |
|
Metsa Board Oyj B
HE:METSB
|
-0.005x |
|
Dongwon Ind
KO:006040
|
0.044x |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
0.024x |
|
Evergreen Steel Corp
TW:2211
|
0.034x |
|
Fengfan Power
SHG:601700
|
0.096x |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
0.026x |
Annual Cash Flow Conversion Efficiency for China Resources Boya Bio pharmaceutical Group Co Ltd (2009–2025)
The table below shows the annual cash flow conversion efficiency of China Resources Boya Bio pharmaceutical Group Co Ltd from 2009 to 2025. View 300294 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥7.46 Billion ≈ $1.09 Billion |
CN¥116.69 Million ≈ $17.07 Million |
0.016x | -60.96% |
| 2024-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
CN¥299.78 Million ≈ $43.87 Million |
0.040x | -54.33% |
| 2023-12-31 | CN¥7.32 Billion ≈ $1.07 Billion |
CN¥641.73 Million ≈ $93.90 Million |
0.088x | +7.06% |
| 2022-12-31 | CN¥7.28 Billion ≈ $1.07 Billion |
CN¥596.44 Million ≈ $87.28 Million |
0.082x | -57.88% |
| 2021-12-31 | CN¥6.92 Billion ≈ $1.01 Billion |
CN¥1.35 Billion ≈ $196.87 Million |
0.194x | +13.42% |
| 2020-12-31 | CN¥4.19 Billion ≈ $613.49 Million |
CN¥718.58 Million ≈ $105.15 Million |
0.171x | +697.00% |
| 2019-12-31 | CN¥3.99 Billion ≈ $583.66 Million |
CN¥-114.51 Million ≈ $-16.76 Million |
-0.029x | -410.15% |
| 2018-12-31 | CN¥3.77 Billion ≈ $551.75 Million |
CN¥34.90 Million ≈ $5.11 Million |
0.009x | +196.56% |
| 2017-12-31 | CN¥2.48 Billion ≈ $363.53 Million |
CN¥-23.82 Million ≈ $-3.49 Million |
-0.010x | -110.28% |
| 2016-12-31 | CN¥2.13 Billion ≈ $312.01 Million |
CN¥198.76 Million ≈ $29.08 Million |
0.093x | +20.98% |
| 2015-12-31 | CN¥1.91 Billion ≈ $279.22 Million |
CN¥147.02 Million ≈ $21.51 Million |
0.077x | -41.59% |
| 2014-12-31 | CN¥923.93 Million ≈ $135.20 Million |
CN¥121.88 Million ≈ $17.84 Million |
0.132x | +25.34% |
| 2013-12-31 | CN¥846.62 Million ≈ $123.89 Million |
CN¥89.11 Million ≈ $13.04 Million |
0.105x | -14.35% |
| 2012-12-31 | CN¥751.60 Million ≈ $109.98 Million |
CN¥92.36 Million ≈ $13.52 Million |
0.123x | -60.41% |
| 2011-12-31 | CN¥262.67 Million ≈ $38.44 Million |
CN¥81.53 Million ≈ $11.93 Million |
0.310x | +147.44% |
| 2010-12-31 | CN¥197.44 Million ≈ $28.89 Million |
CN¥24.77 Million ≈ $3.62 Million |
0.125x | -60.23% |
| 2009-12-31 | CN¥164.49 Million ≈ $24.07 Million |
CN¥51.88 Million ≈ $7.59 Million |
0.315x | -- |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more